Literature DB >> 16458072

Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells.

Kirsten B J Scholten1, Duco Kramer, Esther W M Kueter, Marcus Graf, Thomas Schoedl, Chris J L M Meijer, Marco W J Schreurs, Erik Hooijberg.   

Abstract

Expression of native transgenic T cell receptors in recipient human T cells is often insufficient to achieve highly reactive T cell bulks. Here we show that codon modification of an HPV16E7-specific T cell receptor (TCR), together with omission of mRNA instability motifs and (cryptic) splice sites, leads to a dramatic increase in the expression levels of the transgenic TCRs in human CD8+ T cells. The codon-modified TCRs have been tested in three different configurations in the retroviral vector LZRS: (1) TCRalpha-IRES-GFP in combination with TCRbeta-IRES-NGFR, (2) TCRalpha-IRES-TCRbeta, and (3) TCRalpha-2A-TCRbeta. T cells carrying the codon-modified TCRs are functionally active against target cells loaded with relevant peptide, model tumor cells expressing the specific epitope as well as cervical carcinoma cells. The significant improvements we report here in the functional expression of specific human TCRs will hopefully expedite clinical application of TCR transfer-based immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458072     DOI: 10.1016/j.clim.2005.12.009

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  65 in total

1.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies.

Authors:  Marleen M van Loenen; Renate de Boer; Renate S Hagedoorn; Esther H M van Egmond; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

2.  Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes.

Authors:  Michael S Bennett; Aviva Joseph; Hwee L Ng; Harris Goldstein; Otto O Yang
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

3.  T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.

Authors:  Aude G Chapuis; Daniel N Egan; Merav Bar; Thomas M Schmitt; Megan S McAfee; Kelly G Paulson; Valentin Voillet; Raphael Gottardo; Gunnar B Ragnarsson; Marie Bleakley; Cecilia C Yeung; Petri Muhlhauser; Hieu N Nguyen; Lara A Kropp; Luca Castelli; Felecia Wagener; Daniel Hunter; Marcus Lindberg; Kristen Cohen; Aaron Seese; M Juliana McElrath; Natalie Duerkopp; Ted A Gooley; Philip D Greenberg
Journal:  Nat Med       Date:  2019-06-24       Impact factor: 53.440

4.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

5.  MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.

Authors:  Matthias Leisegang; Susanne Wilde; Stefani Spranger; Slavoljub Milosevic; Bernhard Frankenberger; Wolfgang Uckert; Dolores J Schendel
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

6.  Toward more efficient protein expression: keep the message simple.

Authors:  Stephan Kalwy; James Rance; Robert Young
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

Review 7.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

9.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

10.  T-cell receptor gene therapy of established tumors in a murine melanoma model.

Authors:  John D Abad; Claudia Wrzensinski; Willem Overwijk; Moniek A De Witte; Annelies Jorritsma; Cary Hsu; Luca Gattinoni; Cyrille J Cohen; Chrystal M Paulos; Douglas C Palmer; John B A G Haanen; Ton N M Schumacher; Steven A Rosenberg; Nicholas P Restifo; Richard A Morgan
Journal:  J Immunother       Date:  2008-01       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.